BioCryst Pharmaceuticals Inc (BO1.MU)
- GuruFocus.com
BioCryst Pharmaceuticals Reports Strong Q1 2024 Results, Exceeding Analyst Revenue Forecasts
Significant Growth in ORLADEYO Sales and Strategic Pipeline Advancements Mark the Quarter
- Zacks
BioCryst Pharmaceuticals (BCRX) Reports Q1 Loss, Tops Revenue Estimates
BioCryst (BCRX) delivered earnings and revenue surprises of 26.09% and 8.37%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
- GlobeNewswire
BioCryst Reports First Quarter 2024 Financial Results and Provides Business Update
—Q1 2024 ORLADEYO net revenue grows 30 percent y-o-y to $88.9 million— —Full-year 2024 ORLADEYO revenue guidance adjusted to $390-$400 million (top end of prior guidance range) — —Pipeline programs, including BCX17725 for Netherton syndrome and avoralstat for DME, advancing on schedule into clinical trials— RESEARCH TRIANGLE PARK, N.C., May 06, 2024 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today reported financial results for the first quarter ended March 31, 2024, and pr
